AnaptysBio drops development of ANB032 following trial miss

San Diego, USA-based biotech AnaptysBio (Nasdaq: ANAB) today announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema.

However, ANB032 was well tolerated with no safety signals observed, said AnaptysBio, whose shares nevertheless plunged almost 33% to $15.52.

“While ANB032 was safe and well tolerated, we’re disappointed by these efficacy results in AD and will discontinue further investment in this asset. Moving forward, our resources and capital will be focused on the rest of our exciting autoimmune portfolio,” said Daniel Faga, president and chief executive of Anaptys. “PD-1 is a co-inhibitory receptor found preferentially on activated T cells. We look forward to sharing for rosnilimab, a depleter and agonist targeting PD-1+ T cells, top-line Phase IIb rheumatoid arthritis data in February 2025 and top-line Phase II ulcerative colitis data in Q1 2026, followed by Phase 1b data from our two additional programs,” he added.